I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK) and Australia:

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ASRS 2022

-
Coming soon
03:30 PM
Duration 8mins Virtual
Key Surgical Pearls for the Prevention of Conjunctival Complications Following the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure
Wieland M, Callaway N, Menezes A, Singh N, Malhotra V

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:09 AM
Duration 6mins New York City
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Khanani A, Demetriades AM, Kotecha A, Silverman D, Swaminathan B, Patel V, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:16 AM
Duration 6mins New York City
Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Eichenbaum DA, Wells JA, Lim JI, Danzig C, Asik K, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:26 AM
Duration 6mins New York City
Exploring angiopoietin-2 (Ang-2) signaling in vascular stability patients with diabetic macular edema (DME) receiving faricimab in phase 2 and phase 3 trials
Csaky K, Modi Y, Sheth V, Haskova Z, Westenskow PD, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:10 AM
Duration 6mins New York City
Central Subfield Thickness Fluctuations and Their Impact on Vision Outcomes Over 96 Weeks in the Archway Trial of the PDS
Sheth V, Blotner S, Heinrich D, Gune S, Chakravarthy U

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:31 AM
Duration 6mins New York City
End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD
Rachitskaya A, Blotner S, Heinrich D, Gune S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:12 PM
Duration 4mins New York City
Long-term real-world treatment patterns among patients with diabetic macular edema initiating anti-VEGF: 6-year follow-up using the IRIS® Registry
Leng T, Garmo V, Tabano D, Kim E, Kuo B, Hatfield M, LaPrise A, Singh R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:37 PM
Duration 6mins New York City
Personalized Treatment Interval (PTI) Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
Kitchens JW, Baumal CR, Jaffe GJ, Gerendas BS, Abreu F, Camino A, Asik K, Jain N, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar